Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tumors

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,840 result(s) found for: Tumors. Displaying page 1 of 142.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-023827-34 Sponsor Protocol Number: 1585/10 Start Date*: 2011-05-02
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: PHASE III CLINICAL TRIAL TO ASSESS THE ADDED ROLE OF 68Ga-DOTANOC PET-CT IN PATIENTS WITH NEUROENDOCRINE TUMORS
    Medical condition: neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052399 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004878-99 Sponsor Protocol Number: INCB84344-102 Start Date*: Information not available in EudraCT
    Sponsor Name:Incyte Biosciences International Sàrl
    Full Title: An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants
    Medical condition: Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000830 Acute leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028549 Myeloid leukaemia PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028553 Myeloid leukaemia, chronic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028552 Myeloid leukaemia, acute LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027655 Miscellaneous and site unspecified neoplasms malignant and unspecified HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) ES (Trial now transitioned) DE (Ongoing) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001099-13 Sponsor Protocol Number: CRAD001K24133E1 Start Date*: 2012-05-10
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Extension study to the open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors
    Medical condition: advanced neuroendocrine tumors of gastrointestinal or lung origin
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000240-16 Sponsor Protocol Number: 20110106 Start Date*: 2011-06-12
    Sponsor Name:Skånes Onkologiska Klinik, Skåne University Hospital, Lund
    Full Title: A MULTICENTER PHASE II STUDY EVALUATING EFFICACY AND SAFETY OF 177Lu-DOTA-TATE BASED ON KIDNEY-DOSIMETRY IN PATIENTS WITH DISSEMINATED NEUROENDOCRINE TUMORS
    Medical condition: Metastatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000897-65 Sponsor Protocol Number: MN2 Start Date*: 2006-02-20
    Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA
    Full Title: Therapy of tumors SSTR2 expressing using somatostatine analogs labeled with 90Y and 177 Lu.
    Medical condition: Diagnosis of tumor classified as expressing SSRT2, the main class of tumors to be included in the study are advanced and metastatic neuroendocrine tumors but also breast, lungs and thyroid cancers...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10052399 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000364-30 Sponsor Protocol Number: I4T-MC-JVDA Start Date*: 2021-06-01
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
    Medical condition: Pediatric Solid Tumor CNS Malignancies
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-002512-14 Sponsor Protocol Number: AK2017-2 Start Date*: 2017-09-04
    Sponsor Name:Rigshospitalet
    Full Title: PET/CT imaging of angiogenesis in patients with neuroendocrine tumors using 68Ga-NODAGA-E[c(RGDyK)]2
    Medical condition: Patients with neuroendocrine tumors (gastro-entero-pancreatic and bronchopulmonary)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    20.0 100000004864 10078184 Neuroendocrine tumor of the lung metastatic LLT
    20.0 100000004864 10078183 Neuroendocrine tumor of the lung LLT
    20.0 100000004864 10062476 Neuroendocrine tumor LLT
    20.0 100000004864 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    20.0 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-002605-65 Sponsor Protocol Number: DOTA2013/DOTATER Start Date*: 2013-11-26
    Sponsor Name:Azienda Ospedaliera di Reggio Emilia Arcispedale S.Maria Nuova/IRCCS
    Full Title: Radioreceptor therapy with labeled somatostatin analogues in tumors with high expression of somatostatin receptors.
    Medical condition: Patients with tumors expressing somatostatin receptors.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002312-13 Sponsor Protocol Number: AK2017-1 Start Date*: 2017-08-25
    Sponsor Name:Rigshospitalet
    Full Title: PET/CT imaging of uPAR-expression in patients with neuroendocrine tumors using 68Ga-NOTA-AE105
    Medical condition: Patients with neuroendocrine tumors (gastro-entero-pancreatic and bronchopulmonary)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    20.0 100000004864 10078184 Neuroendocrine tumor of the lung metastatic LLT
    20.0 100000004864 10078183 Neuroendocrine tumor of the lung LLT
    20.0 100000004864 10062476 Neuroendocrine tumor LLT
    20.0 100000004864 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    20.0 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-003927-12 Sponsor Protocol Number: CHUBX2012/28 Start Date*: 2014-03-03
    Sponsor Name:CHU de Bordeaux
    Full Title: Development of an innovative Gallium 68 radiolabeling of DOTATOC (68Ga-DOTATOC) for PET-CT imaging of neuro-endocrine tumors and preliminary clinical evaluation
    Medical condition: neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001613-83 Sponsor Protocol Number: IMMUNeOCT Start Date*: 2017-07-11
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: Octreotide LAR in the induction of immunologic response in patient with neuroendocrine tumors: an interventional pharmacological study
    Medical condition: patient with neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004313-13 Sponsor Protocol Number: 20121001 Start Date*: 2013-01-22
    Sponsor Name:Skåne University Hospital, Dept of Oncology
    Full Title: A prospective study of the use of 68Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors.
    Medical condition: Patients with neuroendocrine tumors, who are going to be diagnosed/evaluated with 68Ga-DOTA-TATE PET/CT instead of standard Octreoscan
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022975-67 Sponsor Protocol Number: 2010-022975-67 Start Date*: 2011-03-31
    Sponsor Name:AZIENDA U.L.S.S. N.8 DI ASOLO
    Full Title: 68Ga-DOTANOC as a PET tool to diagnose nueroendocrine tumors
    Medical condition: Study of tumor neuroendocrin origin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005546-63 Sponsor Protocol Number: DOTATER1_26_15 Start Date*: 2016-05-30
    Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE SANTA MARIA NUOVA/IRCCS DI REGGIO EMILIA
    Full Title: Peptide receptor radionuclide therapy in tumors with high expression of somatostatine receptors.
    Medical condition: Cancer patients with high expression of somatostatin receptors (neurendocrine tumors, thyroid tumors, lung tumors, meningiomas).
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001908-42 Sponsor Protocol Number: V937-013 Start Date*: 2020-10-29
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic Solid Tumors
    Medical condition: Advanced/metastatic solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) HU (Completed) DE (Completed) PL (Completed) PT (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022057-42 Sponsor Protocol Number: 3D-iUS-NCH Start Date*: 2011-03-22
    Sponsor Name:Universität Leipzig
    Full Title: Pilot study to optimise the use and to evaluate the diagnostic value of intraoperative contrast-enhanced 3D-ultrasound with SonoVue® for imaging of intracranial tumors
    Medical condition: Patients with an intracranial tumor and planned operation as well as expected echoic behaviour of the tumor
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004865 10053764 Brain tumor operation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000370-30 Sponsor Protocol Number: 20150706 Start Date*: 2015-11-26
    Sponsor Name:Norrlands University Hospital
    Full Title: Diagnosis and follow up of neuroendocrine tumours with 68Ga-DotaToc PET/CT
    Medical condition: Neuroendocrine tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002205-69 Sponsor Protocol Number: Hepatooma Start Date*: 2009-08-24
    Sponsor Name:Organisation name was not entered
    Full Title: Investigation of Hepatic Tumors with Positron Emission Tomography Using [11C]-Metomidate and [11C]-Acetate Tracers
    Medical condition: This study is planned to determine and compare two new radiotracers (11C-labeled metomidate and acetate) in the detection of malignant and benign hepatic tumors. The detection of hepatocellular car...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002741-21 Sponsor Protocol Number: AAA-Ga-TOC-EU-01 Start Date*: 2014-10-23
    Sponsor Name:Advanced Accelerator Applications SA
    Full Title: Safety and tolerability of 68Ga-DOTATOC for injection in patients with proven gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).
    Medical condition: Patients with proven gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000206-18 Sponsor Protocol Number: PM1183-B-005-14-QT Start Date*: 2015-09-10
    Sponsor Name:PharmaMar S.A., Sociedad Unipersonal
    Full Title: Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients with Selected Solid Tumors
    Medical condition: - small cell lung cancer (SCLC) - head and neck carcinoma (H&N) - neuroendocrine tumors (NETs) - biliary tract carcinoma - endometrial carcinoma - BRCA 1/2-associated metastatic breast carcinoma - ...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 03:48:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA